PHARMACIE BELLEVUE SAINT MARTIN : revenue, balance sheet and financial ratios

In 2024, PHARMACIE BELLEVUE SAINT MARTIN achieves revenue of 3.9 M€. Revenue is growing positively over 9 years (CAGR: +4.9%). Vs 2023: +7%. After deducting consumption (2.4 M€), gross margin stands at 1.5 M€, i.e. a rate of 39%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 428 k€, representing 11.0% of revenue. Warning negative scissor effect: despite revenue change (+7%), EBITDA varies by -20%, reducing margin by 3.7 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 310 k€, i.e. 7.9% of revenue. This profit can be retained or distributed to shareholders.

The debt ratio (= Financial debt / Equity x 100) stands at 56%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 56%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.0 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 8.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.

The liquidity ratio (= Current assets / Current liabilities) stands at 276.33. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 13.0x. Operating income very largely covers interest expenses: high safety margin.

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 2 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 50 days. Excellent situation: suppliers finance 48 days of the operating cycle (retail model). Inventory turnover is 58 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 55 days of revenue, i.e. 599 k€ to permanently finance. Over 2016-2024, WCR increased by +212%, requiring additional financing.

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE BELLEVUE SAINT MARTIN is estimated at 3 591 819 € (range 2 525 893€ - 5 312 759€). With an EBITDA of 428 260€, the sector multiple of 9.2x is applied. The price/revenue ratio is 0.64x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.